April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Characterization of Choroidal Thickness in Birdshot Chorioretinopathy with Active Retinal Vasculitis
Author Affiliations & Notes
  • Jack Shao
    Ophthalmology, Cole Eye Institute, South Euclid, OH
  • Kimberly Baynes
    Ophthalmology, Cole Eye Institute, South Euclid, OH
  • Careen Y Lowder
    Ophthalmology, Cole Eye Institute, South Euclid, OH
  • Sunil K Srivastava
    Ophthalmology, Cole Eye Institute, South Euclid, OH
  • Footnotes
    Commercial Relationships Jack Shao, None; Kimberly Baynes, None; Careen Lowder, Clearside (C), Santen (C); Sunil Srivastava, Alimera (C), allergan (F), Bausch and Lomb (C), bioptigen (P), clearside (F), novartis (F), Regeneron (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 239. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jack Shao, Kimberly Baynes, Careen Y Lowder, Sunil K Srivastava; Characterization of Choroidal Thickness in Birdshot Chorioretinopathy with Active Retinal Vasculitis. Invest. Ophthalmol. Vis. Sci. 2014;55(13):239.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: The purpose of the study was to characterize choroidal thickness in patients with birdshot chorioretinopathy with retinal vasculitis before and after control of disease activity using spectral domain optical coherence tomography (SD-OCT).

Methods: A retrospective, consecutive, case series of all patients birdshot chorioretinopathy with retinal vasculitis in the last 4 years at the Cole Eye Institute, Cleveland Clinic was performed. Inclusion criteria: 1. Patients with Birdhshot Chorioretinopathy with retinal vasculitis and retinal vascular leakage seen at the Cole Eye Institute in the last 5 years 2. Treatment with retisert implants, immunomodulators, or prednisone 3. SD-OCT performed in the study eye with a fluorescein angiography prior and post-treatment 4. Improvement in control of disease activity based on fluorescein angiography We measured choroidal thickness at the fovea in active birdshot chorioretinopathy with diffuse retinal vascular leakage on fluorescein angiography. Pre-treatment choroidal thickness and post-treatment choroidal thickness were recorded.

Results: 16 eyes of 10 patients with birdshot chorioretinopathy were included in the study. 12 eyes were treated with retisert implants, 2 eyes were treated with a combination of cellcept and prednisone, and 2 eyes were treated with oral prednisone alone. All 16 eyes showed significant improvement of retinal vascular leakage by fluorescein angiography with treatment. 2 of 16 eyes had cystoids macular edema based on OCT. 13 of 16 eyes showed decreased choroidal thickness after treatment, 3 showed increased choroidal thickness. The average choroidal thickness prior to treatment was 280.9 um, and after treatment 234.6 um. Overall, there was a 15.8% decrease in choroidal thickness (p < 0.0042).

Conclusions: This is the first study that characterizes reduction of choroidal thickness in birdshot chorioretinopathy with active retinal vascular leakage after resolution of leakage on angiography. Changes in choroidal thickness may be more sensitive than cystoid macular edema in evaluating retinal vasculitis with leakage in birdshot chorioretinopathy and may be another way to monitor disease progression or response to treatment.

Keywords: 452 choroid • 746 uveitis-clinical/animal model • 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound)  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.